[go: up one dir, main page]

IN2012DN01325A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01325A
IN2012DN01325A IN1325DEN2012A IN2012DN01325A IN 2012DN01325 A IN2012DN01325 A IN 2012DN01325A IN 1325DEN2012 A IN1325DEN2012 A IN 1325DEN2012A IN 2012DN01325 A IN2012DN01325 A IN 2012DN01325A
Authority
IN
India
Prior art keywords
alkyl
independently
pi3k
heteroaryl
inhibitors
Prior art date
Application number
Other languages
English (en)
Inventor
Stephen Joseph Shuttleworth
Alexander Richard Liam Cecil
Thomas James Hill
Franck Alexandre Silva
Original Assignee
Karus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0914594A external-priority patent/GB0914594D0/en
Priority claimed from GBGB1005584.6A external-priority patent/GB201005584D0/en
Application filed by Karus Therapeutics Ltd filed Critical Karus Therapeutics Ltd
Publication of IN2012DN01325A publication Critical patent/IN2012DN01325A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IN1325DEN2012 2009-08-20 2010-08-19 IN2012DN01325A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0914594A GB0914594D0 (en) 2009-08-20 2009-08-20 Compounds
GBGB1005584.6A GB201005584D0 (en) 2010-04-01 2010-04-01 Compounds
PCT/GB2010/051370 WO2011021038A1 (fr) 2009-08-20 2010-08-19 Composés hétérocycliques tricycliques en tant qu'inhibiteurs de phosphoinositide 3-kinase

Publications (1)

Publication Number Publication Date
IN2012DN01325A true IN2012DN01325A (fr) 2015-06-05

Family

ID=42756474

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1325DEN2012 IN2012DN01325A (fr) 2009-08-20 2010-08-19

Country Status (15)

Country Link
US (4) US9200007B2 (fr)
EP (1) EP2467387B1 (fr)
JP (1) JP5746172B2 (fr)
CN (1) CN102498115B (fr)
AU (1) AU2010286168B2 (fr)
BR (1) BR112012003955A2 (fr)
CA (1) CA2771594C (fr)
ES (1) ES2534326T3 (fr)
IL (1) IL217903A (fr)
IN (1) IN2012DN01325A (fr)
MX (1) MX2012002059A (fr)
NZ (1) NZ597983A (fr)
PL (1) PL2467387T3 (fr)
WO (1) WO2011021038A1 (fr)
ZA (1) ZA201200910B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN01325A (fr) 2009-08-20 2015-06-05 Karus Therapeutics Ltd
BR112013014914B8 (pt) * 2010-12-16 2020-08-04 Hoffmann La Roche composto, composição farmacêutica e uso de um composto
AU2015268776B2 (en) * 2010-12-16 2017-04-13 Genentech, Inc. Tricyclic PI3k inhibitor compounds and methods of use
ES2661510T3 (es) 2011-12-15 2018-04-02 Novartis Ag Uso de inhibidores de la actividad o función de PI3K
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
CN107573363A (zh) * 2012-09-20 2018-01-12 Udc 爱尔兰有限责任公司 供电子应用的氮杂二苯并呋喃和包含氮杂二苯并呋喃的电子器件
AU2013343291B2 (en) 2012-11-07 2018-05-10 Karus Therapeutics Ltd Novel histone deacetylase inhibitors and their use in therapy
EA035391B1 (ru) 2012-11-08 2020-06-05 Ризен Фармасьютикалз Са Фармацевтические композиции, содержащие ингибитор pde4 и ингибитор pi3-дельта или двойной ингибитор pi3-дельта-гамма киназы
AR095443A1 (es) * 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii Heterociclos condensados con acción sobre atr
LT2994465T (lt) 2013-05-10 2018-10-10 Karus Therapeutics Limited Nauji histono deacetilazės inhibitoriai
US9814037B2 (en) * 2013-06-28 2017-11-07 Intel Corporation Method for efficient channel estimation and beamforming in FDD system by exploiting uplink-downlink correspondence
CN104557955B (zh) * 2013-10-23 2017-05-03 上海汇伦生命科技有限公司 作为PI3K/mTOR抑制剂的三环类化合物，其制备方法和用途
GB201402431D0 (en) * 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514756D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514754D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
AU2016369528B2 (en) 2015-12-16 2021-04-22 Genentech, Inc. Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer
EP4186910A1 (fr) 2016-06-22 2023-05-31 Vanderbilt University Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN109890388B (zh) 2016-11-07 2023-03-28 范德比尔特大学 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
US10961253B2 (en) 2016-11-07 2021-03-30 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M4
JP7097623B2 (ja) 2016-11-07 2022-07-08 ヴァンダービルト ユニヴァーシティ ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
GB201702938D0 (en) 2017-02-23 2017-04-12 Univ Southampton Methods of generating and screening compartmentalised peptides libraries
US11376254B2 (en) 2017-12-05 2022-07-05 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M4
TW201930311A (zh) 2017-12-05 2019-08-01 泛德比爾特大學 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑
US11318134B2 (en) 2018-01-10 2022-05-03 Recurium Ip Holdings, Llc Benzamide compounds
WO2022169882A1 (fr) 2021-02-03 2022-08-11 Verge Analytics, Inc. Procédés et traitement d'une infection virale provoquée par le sars-cov-2
WO2023020604A1 (fr) * 2021-08-20 2023-02-23 南京大美生物制药有限公司 Dérivé hétérocyclique et hétéroaryle contenant de l'azote à cinq chaînons et son utilisation

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1445742A1 (de) 1963-11-06 1968-12-19 Bayer Ag Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen
US4017500A (en) 1973-07-16 1977-04-12 Schering Corporation Certain 8-amino-1,7-naphthyridines
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
EP1277738B1 (fr) 2000-04-27 2011-03-30 Astellas Pharma Inc. Derives d'heteroaryle condenses
CA2414468A1 (fr) 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones et leur utilisation comme inhibiteurs des proteine kinases
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
FR2846657B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2557541C (fr) 2004-02-26 2014-12-16 Aska Pharmaceutical Co., Ltd. Derives de pyrimidine
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
ZA200710379B (en) 2005-05-20 2009-05-27 Vertex Pharma Pyrrolopyridines useful as inhibitors of protein kinase
CA2635899A1 (fr) 2006-01-19 2007-07-26 Osi Pharmaceuticals, Inc. Inhibiteurs de kinase heterobicycliques fusionnes
CN101511840A (zh) * 2006-04-26 2009-08-19 吉宁特有限公司 磷酸肌醇3-激酶抑制剂化合物及其使用方法
BRPI0710866A2 (pt) * 2006-04-26 2012-08-14 Hoffmann La Roche compostos farmacÊuticos
ES2365258T3 (es) 2006-06-26 2011-09-27 Ucb Pharma S.A. Derivados de tiazol condensados como inhibidores de quinasa.
WO2008064018A1 (fr) 2006-11-13 2008-05-29 Eli Lilly & Co. Thiénopyrimidinones destinées au traitement de troubles inflammatoires et de cancers
MX2009008253A (es) 2007-01-31 2009-10-12 Vertex Pharma Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
WO2008121257A1 (fr) 2007-03-28 2008-10-09 Merck & Co., Inc. Dérivés de pyrido[2,3-d]pyrimidine substitués en tant que modulateurs de récepteur de cannabinoïde-1
US20100179143A1 (en) 2007-05-29 2010-07-15 Smithkline Beecham Corporation Naphthyridine, derivatives as p13 kinase inhibitors
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
US9029411B2 (en) * 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
CA2732087A1 (fr) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Naphtyridines substituees et leur utilisation en tant que medicaments
WO2010037765A2 (fr) 2008-10-03 2010-04-08 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
US8981087B2 (en) 2009-07-29 2015-03-17 Karus Therapeutics Limited Benzo [E] [1,3] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors
IN2012DN01325A (fr) 2009-08-20 2015-06-05 Karus Therapeutics Ltd
US20110207736A1 (en) 2009-12-23 2011-08-25 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds
EP2736895B1 (fr) 2011-07-27 2016-01-06 Astrazeneca AB Deruves de 2-(2,4,5-substituted-anilino) pyrimidine comme modulatuers du egfr utiles dans le traitement du cancer
WO2013017480A1 (fr) 2011-07-29 2013-02-07 Cellzome Limited Dérivés de pyrazolo[4,3-c]pyridine en tant qu'inhibiteurs de jak
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
KR20150087850A (ko) 2012-11-20 2015-07-30 제넨테크, 인크. Egfr 돌연변이체를 함유하는 t790m의 억제제로서의 아미노피리미딘 화합물
LT2994465T (lt) 2013-05-10 2018-10-10 Karus Therapeutics Limited Nauji histono deacetilazės inhibitoriai
WO2014194254A1 (fr) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Traitement anticancer au moyen de modulateurs isoformes de la kinase p13
WO2014210354A1 (fr) 2013-06-28 2014-12-31 Genentech, Inc. Composés d'azaindazole en tant qu'inhibiteurs de la t790m contenant des mutants de l'egfr
EP3054953B1 (fr) 2013-10-10 2020-07-01 Acetylon Pharmaceuticals, Inc. Inhibiteurs de hdac en combinaison avec des inhibiteurs de pi3k, pour le traitement du lymphome non hodgkinien
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321730D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201514756D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
AU2010286168A1 (en) 2012-03-08
IL217903A (en) 2017-08-31
EP2467387B1 (fr) 2015-01-07
CA2771594A1 (fr) 2011-02-24
EP2467387A1 (fr) 2012-06-27
US20190040079A1 (en) 2019-02-07
IL217903A0 (en) 2012-03-29
MX2012002059A (es) 2012-04-19
JP5746172B2 (ja) 2015-07-08
US20180009826A1 (en) 2018-01-11
ES2534326T3 (es) 2015-04-21
US20160108057A1 (en) 2016-04-21
US9200007B2 (en) 2015-12-01
US9938290B2 (en) 2018-04-10
ZA201200910B (en) 2013-05-29
CA2771594C (fr) 2018-05-01
AU2010286168B2 (en) 2014-05-15
JP2013502404A (ja) 2013-01-24
US10501478B2 (en) 2019-12-10
US9580442B2 (en) 2017-02-28
WO2011021038A1 (fr) 2011-02-24
CN102498115A (zh) 2012-06-13
US20120178737A1 (en) 2012-07-12
NZ597983A (en) 2014-05-30
CN102498115B (zh) 2016-12-07
PL2467387T3 (pl) 2015-08-31
BR112012003955A2 (pt) 2017-09-26

Similar Documents

Publication Publication Date Title
IN2012DN01325A (fr)
PH12017501192A1 (en) Certain amino-pyridazines, compositions thereof, and methods of their use
GEP201706728B (en) Noxious organism control agent
MY163498A (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
MX338114B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
MY155517A (en) Heterocyclic derivatives
TN2011000400A1 (en) Inhibitors of beta-secretase
CA2875877C (fr) Inhibiteurs syk
MX2012015023A (es) Derivado novedoso de nicotinamida o sal del mismo.
EA201391098A1 (ru) C-28-амины c-3-модифицированных производных бетулиновой кислоты в качестве ингибиторов созревания вич
MY172924A (en) Neprilysin inhibitors
JO3465B1 (ar) مركب متغاير الحلقه واستخدامه
MD20140023A2 (ro) Derivaţi de pirolpirimidină şi purină
MX2010006421A (es) Compuestos organicos.
MD4582B1 (ro) Derivaţi ai 1-fenil-1H-benzimidazolului ca inhibitori ai protein kinazei
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
MX2015008971A (es) Derivados de pirimidina pirido- o pirrolo-fusionados como inhibidores de autotaxina para tratar dolor.
MX2009012613A (es) Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
MX2011011764A (es) Compuestos de carboxamida y su uso como inhibidores de calpaina.
IN2014DN07509A (fr)
PH12012501643A1 (en) Pyrazolopyrimidine compounds and their use as pde 10 inhibitors
PH12015502429A1 (en) Dicarboxylic acid compound
PH12013501840A1 (en) Nitrogen-containing saturated heterocyclic compound
MX2011012068A (es) Nucleosidos 2'-fluoro arabino y su utilizaicon.